Bio­gen, Sam­sung Bioepis look to carve up a block­buster Roche fran­chise with deep dis­count biosim­i­lar

Bio­gen and their biosim­i­lar part­ners at Sam­sung Bioepis are rolling out their copy­cat ver­sion of Roche’s an­ti-VEGF block­buster Lu­cen­tis to­day, 8 months af­ter it was ap­proved by the FDA. And they’re plan­ning to dive straight in­to a wet AMD mar­ket dom­i­nat­ed by Re­gen­eron’s Eylea with a hefty 40% dis­count off the brand­ed orig­i­nal.

The part­ners say they’ll of­fer By­ooviz for $1,130 per sin­gle-use vial, look­ing to an­gle in on a fran­chise that de­liv­ered $1.35 bil­lion to Roche sub­sidiary Genen­tech from US sales last year. Ex-US sales topped $2 bil­lion for No­var­tis, which shares com­mer­cial rights on the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.